Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
Abstract
Uveal melanoma is the most common intraocular cancer in adults, driven by activating mutations in GNAQ or GNA11 , which encode the G proteins Gαq and Gα11. Currently, therapeutic options for uveal melanoma, particularly metastatic uveal melanoma, remain limited. Through an isogenic CRISPR screening approach, we identify EP300 , which encodes the protein lysine acetyltransferase p300, as a top synthetic lethal vulnerability in the context of GNAQ mutation. Notably, CREBBP , which encodes the closely related paralogue CBP, also emerges among the top-ranked candidates. Mechanistically, we find that p300 and CBP support YAP-dependent transcription downstream of oncogenic Gαq in uveal melanoma through interactions with YAP at chromatin. These interactions enhance H3K27 acetylation at the promoters and putative enhancers of YAP target genes and promote the recruitment of RNA polymerase II and CDK9. Using multiple in vivo models representing clinically relevant stages of Gαq-mutant uveal melanoma, we find that p300 inhibition, by both genetic and pharmacological approaches, profoundly impairs tumor growth and metastasis. Taken together, this study establishes p300 as a potential therapeutic target for Gαq-driven uveal melanoma, which is dependent on unrestrained YAP signaling.
Related
- SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers
- In vivo intercellular CRISPR screens using viral proximity barcoding reveal regulators of tumor-immune interactions
- FANCM restrains structural genome evolution and defines a synthetic lethal dependency in BRCA1-deficient breast cancer
- Predicting resistance to synthetic lethal therapies in cancer
- Cell-state-dependent responses to PLK1 inhibition reveal a non-canonical microtubule-endolysosomal vulnerability in quiescent leukemia stem cells
BibTeX
@article{zhang2026synthetic,
title = {{Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas}},
author = {Gui-Ming Zhang and Junling Yuan and Liang Chen and Xuan-Yu Jin and Zhong-Lu Ren and Yan-Ling Zhou and Runhua Zhou and Ya-Fei Xiao and Jing-Wei Wang and Xi-An Zhang and Chongzhi Bai and Zhijie Li and Yi-Lei Li and Le Yu},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-77999-8},
url = {https://www.nature.com/articles/s41467-026-77999-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
AU - Gui-Ming Zhang
AU - Junling Yuan
AU - Liang Chen
AU - Xuan-Yu Jin
AU - Zhong-Lu Ren
AU - Yan-Ling Zhou
AU - Runhua Zhou
AU - Ya-Fei Xiao
AU - Jing-Wei Wang
AU - Xi-An Zhang
AU - Chongzhi Bai
AU - Zhijie Li
AU - Yi-Lei Li
AU - Le Yu
PY - 2026
DA - 2026/10/02
JO - Nature Communications
DO - 10.1038/s41467-026-77999-8
UR - https://www.nature.com/articles/s41467-026-77999-8
AB - Uveal melanoma is the most common intraocular cancer in adults, driven by activating mutations in GNAQ or GNA11 , which encode the G proteins Gαq and Gα11. Currently, therapeutic options for uveal melanoma, particularly metastatic uveal melanoma, remain limited. Through an isogenic CRISPR screening approach, we identify EP300 , which encodes the protein lysine acetyltransferase p300, as a top synthetic lethal vulnerability in the context of GNAQ mutation. Notably, CREBBP , which encodes the closely related paralogue CBP, also emerges among the top-ranked candidates. Mechanistically, we find that p300 and CBP support YAP-dependent transcription downstream of oncogenic Gαq in uveal melanoma through interactions with YAP at chromatin. These interactions enhance H3K27 acetylation at the promoters and putative enhancers of YAP target genes and promote the recruitment of RNA polymerase II and CDK9. Using multiple in vivo models representing clinically relevant stages of Gαq-mutant uveal melanoma, we find that p300 inhibition, by both genetic and pharmacological approaches, profoundly impairs tumor growth and metastasis. Taken together, this study establishes p300 as a potential therapeutic target for Gαq-driven uveal melanoma, which is dependent on unrestrained YAP signaling.
SN - 2041-1723
ER -